Meeting
2011 ASCO Annual Meeting
Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).
Authors
K. B. Kim
University of Texas M. D. Anderson Cancer Center, Houston, TX
K. B. Kim , K. T. Flaherty , P. B. Chapman , J. A. Sosman , A. Ribas , G. A. McArthur , R. K. Amaravadi , R. J. Lee , K. B. Nolop , I. Puzanov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT00405587
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8519)
Abstract #
8519
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
First Author: Zeynep Eroglu
Poster
2013 ASCO Annual Meeting
Open-label, multicenter, single-arm, phase I, dose-dscalation with efficacy tail extension study of vemurafenib in pediatric patients with surgically incurable and unresectable stage IIIc or IV melanoma harboring BRAFV600 mutations (NCT01519323).
First Author: Fariba Navid
Poster
2019 ASCO Annual Meeting
Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.
First Author: Baptiste Louveau
Poster
2017 ASCO Annual Meeting
Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).
First Author: Stergios J. Moschos